• News

"Providers, Regulators Explore Type 2 Therapies for Type 1 Diabetes" - Regina Schaffer

  • Healio: Endocrine Today
  • New York, NY
  • (May 23, 2019)

For most children and adults with type 1 diabetes, day-to-day disease management remains difficult despite improvements in insulin formulations and delivery and advancements in diabetes technologies during the past decade. Only 17 percent  of children and 21 percent of adults with type 1 diabetes meet HbA1c targets outlined in American Diabetes Association guidelines, with glycemic control worsening over eight years of follow-up among adolescents, in particular, according to an analysis of registry data. “Even with patient adoption of diabetes technology and newer insulins for blood glucose management, patients with type 1 diabetes struggle with tremendous and at times unpredictable variability in their glucose levels on a daily basis,” said Carol Levy, MD, clinical director of the Mount Sinai Diabetes Center. Dr. Levy added, “Patients struggle with variable responses from an insulin injection for meals as well as confounding factors like exercise, stress, alcohol and many others, which impact daily glucose levels. We need to think about what other support we can provide for patients in addition to injectable treatments.”

— Carol Levy, MD, Clinical Director, Mount Sinai Diabetes Center, Associate Professor, Medicine, Endocrinology, Diabetes, Bone Disease, Icahn School of Medicine at Mount Sinai

Learn more